E-LIB Suche - Ergebnisse für: Dignass, A.

1

BOC.04.2: TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLO..:

Sands, B.E. ; D'haens, G. ; Clemow, D.B....
Digestive and Liver Disease. 56 (2024) - p. S121-S122 , 2024

Link: https://doi.org/10.1016/..

2

DOP49 Guselkumab improves health-related quality of life as..:

Panés, J ; Dignass, A ; Lichtenstein, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i161-i162 , 2024

Link: https://doi.org/10.1093/..

3

P732 Lack of concordance between patient-reported, physicia..:

D'Amico, F ; Gomollón, F ; Bamias, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1372-i1373 , 2024

Link: https://doi.org/10.1093/..

4

DOP52 Guselkumab improves symptoms of fatigue in patients w..:

Dignass, A ; Panés, J ; Rubin, D T...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i166-i167 , 2024

Link: https://doi.org/10.1093/..

5

P377 Proportion of IBD patients with suboptimal control in ..:

Dignass, A ; D'Amico, F ; Gomollón, F...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i794-i795 , 2024

Link: https://doi.org/10.1093/..

6

P808 Use of intestinal ultrasound influences the proportion..:

Dignass, A ; D'Amico, F ; Gomollón, F...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1504-i1505 , 2024

Link: https://doi.org/10.1093/..

7

IBD-PODCAST Spain: A Close Look at Current Daily Clinical P..:

Vega, P. ; Huguet, J. M. ; Gómez, E....
Digestive Diseases and Sciences. 69 (2024) 3 - p. 749-765 , 2024

Link: https://doi.org/10.1007/..

8

P1037 Treatment sequences and time on specific treatments i..:

Dignass, A ; Teich, N ; Kudernatsch, R...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1870-i1872 , 2024

Link: https://doi.org/10.1093/..

9

P954 Cumulative response to guselkumab through week 24 of i..:

Rubin, D ; Sands, B ; Lichtenstein, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1732-i1733 , 2024

Link: https://doi.org/10.1093/..

10

P687 Durability of recaptured response to ozanimod during t..:

Dignass, A ; Regueiro, M ; Colombel, J F...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i817-i818 , 2023

Link: https://doi.org/10.1093/..

11

DOP43 Extended induction in the True North OLE study: ozani..:

Dignass, A ; Regueiro, M ; Colombel, J F...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i110-i111 , 2023

Link: https://doi.org/10.1093/..

12

P319 Characteristics of filgotinib-treated patients with Ul..:

Kobayashi, T ; Dignass, A ; Roblin, X...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i459-i460 , 2023

Link: https://doi.org/10.1093/..

13

A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WIT..:

Danese, S ; Dignass, A ; Matsuoka, K...
Journal of the Canadian Association of Gastroenterology. 6 (2023) Supplement_1 - p. 28-29 , 2023

Link: https://doi.org/10.1093/..

14

DOP39 Endoscopic, histologic, and combined outcomes with re..:

Vermeire, S ; Dignass, A ; Colombel, J F...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i103-i104 , 2023

Link: https://doi.org/10.1093/..

15

P493 QUASAR Induction Study 1 Cumulative Response to Guselk..:

Peyrin-Biroulet, L ; Rubin, D ; Lichtenstein, G...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i624-i625 , 2023

Link: https://doi.org/10.1093/..